(Q37504310)

20 August 2017

1 reference

title

Pulmonary complications: one of the most challenging complications of systemic sclerosis (English)

1 reference

20 August 2017

A U Wells

1

1 reference

PubMed ID

19487223

20 August 2017

V Steen

series ordinal

2

1 reference

PubMed ID

19487223

20 August 2017

G Valentini

series ordinal

3

1 reference

20 August 2017

1 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

48 Suppl 3

1 reference

20 August 2017

iii40-4

1 reference

Changes in causes of death in systemic sclerosis, 1972-2002

20 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Evaluation and management of alveolitis and interstitial lung disease in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

The lung in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Isolated diffusing capacity reduction in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

General considerations for lung function testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Standardisation of the measurement of lung volumes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Standardisation of the single-breath determination of carbon monoxide uptake in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Interpretative strategies for lung function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Pulmonary vascular changes in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Interstitial lung disease in systemic sclerosis: a simple staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

New therapeutic strategies for systemic sclerosis--a critical analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP109

10.1093/RHEUMATOLOGY/KEP109

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19487223